Ariad Pharmaceuticals Inc.'s Iclusig (ponatinib) has been approved in Japan for second-line use in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) through Asian licensee Otsuka Pharmaceutical Co. Ltd.
A 15 mg tablet formulation of the oral kinase inhibitor is indicated for CML patients resistant or intolerant to previous...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?